LLY

1,045.2

+0.07%↑

JNJ

246.17

+0.3%↑

ABBV

228.99

+0.04%↑

NVS

167.04

+1.08%↑

MRK

123.55

+1.05%↑

LLY

1,045.2

+0.07%↑

JNJ

246.17

+0.3%↑

ABBV

228.99

+0.04%↑

NVS

167.04

+1.08%↑

MRK

123.55

+1.05%↑

LLY

1,045.2

+0.07%↑

JNJ

246.17

+0.3%↑

ABBV

228.99

+0.04%↑

NVS

167.04

+1.08%↑

MRK

123.55

+1.05%↑

LLY

1,045.2

+0.07%↑

JNJ

246.17

+0.3%↑

ABBV

228.99

+0.04%↑

NVS

167.04

+1.08%↑

MRK

123.55

+1.05%↑

LLY

1,045.2

+0.07%↑

JNJ

246.17

+0.3%↑

ABBV

228.99

+0.04%↑

NVS

167.04

+1.08%↑

MRK

123.55

+1.05%↑

Inicio・Lista de Acciones・Vaxart Inc

Vaxart Inc

Abierto

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

Métricas clave
By Trading Economics
Ingresos	6.8M -8.1M
Ventas	33M 72M
Margen de beneficios	-11.242
Empleados	105
EBITDA	6.7M -5.4M

Dividendos
By Dow Jones
Próximas Ganancias	19 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	45M 136M
Apertura anterior	0
Cierre anterior	0

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

0.4007 / 0.4252 Soporte y Resistencia

Vaxart Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 feb 2026, 22:53 UTC

Adquisiciones, fusiones, absorciones

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 feb 2026, 22:36 UTC

Ganancias

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 feb 2026, 22:32 UTC

Ganancias

Woodside Energy Fiscal Year Net Profit Falls 24%

23 feb 2026, 23:58 UTC

Charlas de Mercado

Ganancias

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 feb 2026, 23:58 UTC

Charlas de Mercado

Ganancias

Global Energy Roundup: Market Talk

23 feb 2026, 23:47 UTC

Charlas de Mercado

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 feb 2026, 23:43 UTC

Charlas de Mercado

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 feb 2026, 23:41 UTC

Adquisiciones, fusiones, absorciones

Crescent Capital Partners Owns 53% of ClearView Wealth

23 feb 2026, 23:40 UTC

Adquisiciones, fusiones, absorciones

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 feb 2026, 23:40 UTC

Adquisiciones, fusiones, absorciones

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 feb 2026, 23:40 UTC

Charlas de Mercado

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 feb 2026, 23:40 UTC

Adquisiciones, fusiones, absorciones

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 feb 2026, 23:39 UTC

Adquisiciones, fusiones, absorciones

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 feb 2026, 23:31 UTC

Ganancias

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 feb 2026, 23:31 UTC

Ganancias

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 feb 2026, 23:28 UTC

Ganancias

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 feb 2026, 23:28 UTC

Ganancias

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 feb 2026, 23:28 UTC

Ganancias

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 feb 2026, 23:27 UTC

Ganancias

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 feb 2026, 23:24 UTC

Charlas de Mercado

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 feb 2026, 22:38 UTC

Adquisiciones, fusiones, absorciones

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 feb 2026, 22:31 UTC

Ganancias

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 feb 2026, 22:24 UTC

Ganancias

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 feb 2026, 22:22 UTC

Ganancias

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 feb 2026, 22:22 UTC

Ganancias

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 feb 2026, 22:22 UTC

Ganancias

Viva Energy FY Underlying Ebitda A$700.9 Million

23 feb 2026, 22:22 UTC

Ganancias

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 feb 2026, 22:21 UTC

Ganancias

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 feb 2026, 22:21 UTC

Ganancias

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 feb 2026, 22:20 UTC

Ganancias

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Comparación entre iguales

Cambio de precio

Vaxart Inc previsión

Consenso

By TipRanks

0 ratings

Comprar

Mantener

Vender

De acuerdo con 0 analistas que ofrecen calificaciones bursátiles a para Vaxart Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.4007 / 0.4252Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.